Alivexis Announces Publication of ModBind_dG™ Simulation Technology Paper in PNAS
Key facts
- Alivexis Announces Publication of ModBind_dG™ Simulation Technology Paper in PNAS
- Alivexis, Inc. announces the publication of a research paper on ModBind_dG™, the latest version of its computational drug discovery platform, in the Proceedings of the National Academy of Sciences (PNAS). This technology enables rapid and accurate prediction of ligand binding affinity—up to thousands of times faster than existing methods—without requiring reference compound data, marking a significant advancement in drug discovery.
- Source: PR TIMES
- Date: Tue Jun 16 2026 23:00:01 GMT+0900 (Japan Standard Time)
Direct answer
Alivexis, Inc. announces the publication of a research paper on ModBind_dG™, the latest version of its computational drug discovery platform, in the Proceedings of the National Academy of Sciences (PNAS). This technology enables rapid and accurate prediction of ligand binding affinity—up to thousands of times faster than existing methods—without requiring reference compound data, marking a significant advancement in drug discovery.
- Citation
- Alivexis Announces Publication of ModBind_dG™ Simulation Technology Paper in PNAS (Tue Jun 16 2026 23:00:01 GMT+0900 (Japan Standard Time)), PR TIMES
- Source
- PR TIMES
- Date
- Tue Jun 16 2026 23:00:01 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Alivexis, Inc. announces the publication of a research paper on ModBind_dG™, the latest version of its computational drug discovery platform, in the Proceedings of the National Academy of Sciences (PNAS). This technology enables rapid and accurate prediction of ligand binding affinity—up to thousands of times faster than existing methods—without requiring reference compound data, marking a significant advancement in drug discovery.
AI Analysis
Frequently Asked Questions
- Q: What is the key feature of ModBind_dG™?
- A: It predicts absolute binding free energy without reference compounds, up to thousands of times faster.
- Q: Who benefits from this technology?
- A: Pharmaceutical and biotech researchers benefit from faster compound evaluation.
- Q: Why is PNAS publication important?
- A: It signifies peer-recognized scientific validity and global academic endorsement.
- Q: What is Alivexis' business model?
- A: Dual focus on in-house pipeline development and collaborative R&D with pharma partners.
- Q: What's next for the technology?
- A: Further acceleration and expansion to diverse drug targets are underway.